Conference Proceedings
Clinical Utility of Circulating Tumor (ct)DNA Quantity and Kinetics in Patients Undergoing CAR T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma
Imogen Caldwell, Yan Zhuang Yap, Mark R Dowling, Javad Saghebi, Aaron Jun Ning Wong, Roxane Legaie, Rainier Arnolda, Clarissa Wilson, Danielle Ignacio, Nicole O'Leary, Stephanie Yaung, Bowdoin Su, Corinna Woestmann, Michael Dickinson, Ella Thompson, Piers Blombery
BLOOD | ELSEVIER | Published : 2023
Abstract
Background: CD19-targeted CAR T-cells are approved for relapsed and/or refractory (RR) aggressive B-cell lymphomas. While some patients experience durable remissions, others do not respond or relapse. Improved patient selection and early identification of patients who may need additional therapies are thus necessary. ctDNA is a promising biomarker for prognostication in DLBCL and has the potential to guide therapeutic decisions. We aimed to explore the possible clinical utility of ctDNA quantitation in patients with aggressive B-cell lymphomas undergoing CAR T-cell therapy. Methods: Twenty-eight patients undergoing CAR T-cell therapy as part of standard of care pathways for RR..
View full abstract